De-Escalated Adjuvant Treatment for Advanced MMR Deficient Mixed Endometrioid/Clear Cell Endometrial Carcinoma with PD-1 Inhibition Alone: A Case Report
Histotype-agnostic adjuvant monotherapy with checkpoint immune inhibitors alone appears to be a highly effective even in the rare mixed endometrial carcinomas if MMR protein deficient as described in this case report.
Authors
- Malte Renz (ORCID: https://orcid.org/0000-0001-9535-7560)
- Susan M. Lang (ORCID: https://orcid.org/0000-0003-0950-1138)
- Ravali A. Reddy (ORCID: https://orcid.org/0009-0004-0336-8801)
- Danielle Blemur
Institutions
- Charité - Universitätsmedizin Berlin (DE)
- Stanford University (US)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1159/000540357
- Citations
- 1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.58
Funders
- Stanford Cancer Institute